Cellectis Announces 2026 Shareholders' Meeting, Director Renewals, and Capital Increase Proposals

Cellectis S.A. filed a Form 6-K on May 20, 2026, announcing its Combined General Meeting of Shareholders scheduled for June 25, 2026, in Paris. The meeting agenda includes several key proposals. Notably, the Board is seeking to renew the appointments of four directors—Mr. Jean-Pierre Garnier, Mr. Laurent Arthaud, Mr. Rainer Boehm, and Ms. Cécile Chartier—for three-year terms. Additionally, the company proposes to increase the age limit for the Chairman of the Board from 80 to 85 years. On the financial front, shareholders will vote on approving the 2025 annual and consolidated financial statements, which reported a loss of approximately €61.8 million and $67.6 million, respectively. The company is also requesting various delegations of authority to increase share capital by up to 50% (approx. €2.5 million nominal) and issue debt securities up to €300 million. These authorizations are intended to facilitate financing through various channels, including "At-the-market" programs and private placements with specialized healthcare and biotech investors. The Board also seeks authorization for share buybacks and the issuance of stock options and free shares for employees.